Sareum Holdings have published a Trading Update ahead of their full year results. We have published research on this which is attached, and a snapshot of the research is below.
The specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases has given a trading update ahead of its full year results for the year ended 30 June 2021, expected for release in October 2021. Despite recent delays in compound supply lea ....
19 Aug 2021
Strengthening balance sheet as TYK2/JAK1 programme approaches the clinical phase
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strengthening balance sheet as TYK2/JAK1 programme approaches the clinical phase
Sareum Holdings plc (SAR:LON) | 20.5 0.8 24.2% | Mkt Cap: 20.2m
- Published:
19 Aug 2021 - Author:
-
Pages:
7
Sareum Holdings have published a Trading Update ahead of their full year results. We have published research on this which is attached, and a snapshot of the research is below.
The specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases has given a trading update ahead of its full year results for the year ended 30 June 2021, expected for release in October 2021. Despite recent delays in compound supply lea ....